Condition: Atrial Fibrillation · Supraventricular Arrhythmia · Ventricular Arrhythmias and Cardiac Arrest · Sponsor: Northwell Health
This study will enroll patients initiating Bruton Tyrosine Kinase (BTK) inhibitors without history of documented arrhythmia while on therapy using the Medtronic LINQ-2 insertable cardiac monitor (ILR). The incidence of new onset atrial fibrillation (AF) and other arrhythmia will be determined. Actions taken in response to device detected arrhythmia will be recorded.
This description comes directly from the study's public registry record.
Efstathia Mihelis · 212-434-6614 · emihelis@northwell.edu
Robert S Copeland-Halperin, MD · 718-470-7330
Always discuss trial participation with your own doctor first.
| Northwell (Northshore University/Long Island Jewish Hospitals) | New Hyde Park, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05643235